ASS1 and colorectal carcinoma: Our findings indicate that ASS1 shows potential as a viable therapeutic target for treating CRC and serves as a dependable marker linked to metabolic reprogramming in CRC; meanwhile, EVO exhibits great potential as a natural-derived agent for CRC therapy by integrating metabolic intervention and signaling pathway regulation.